Trial Profile
Clinical trial, Phase III, randomized, prospective, unicentric, double-blind and placebo-controlled, to estimate the efficacy and safety of intravenous Levosimendan, in the first 24 hours after primary angioplasty, in patients with acute coronary syndrome with ST-segment elevation
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Oct 2023
Price :
$35
*
At a glance
- Drugs Levosimendan (Primary)
- Indications Myocardial infarction
- Focus Therapeutic Use
- Acronyms LEVOCEST
- 22 Oct 2023 Status changed from recruiting to completed.
- 05 Apr 2018 New trial record